Scholarlink

<p>TERT promoter mutation is associated with poor prognosis in differentiated thyroid carcinoma, with US features varying by mutation status. However, this correlation in anaplastic thyroid carcinoma (ATC) is understudied. We investigated the association between clinicopathological characteristics and US features of ATC with TERT mutation status and prognosis. From November 1994 to May 2022, 58 ATC nodules from 58 patients were analyzed. Two radiologists retrospectively reviewed US features based on the revised K-TIRADS and ACR-TIRADS. Of all 58 ATC nodules, 32 nodules were tested for TERT promoter mutation and detected in 11. TERT promoter-mutated ATC was larger than TERT wild-type ATC (<i>p</i> = 0.032); however, no other differences were observed. ATC with survival period of less than 12&#xa0;months were more likely to have lymph node metastasis (<i>p</i> = 0.012) or distant metastasis at diagnosis (<i>p</i> &lt; 0.001), larger size on US (<i>p</i> = 0.005), and suspicion for gross extrathyroidal extension on US (<i>p</i> = 0.04) compared to ATC with survival period of 12&#xa0;months or more. Advanced disease at diagnosis was a critical factor associated with 1-year survival in patients with ATC, whereas the TERT promoter mutation status was not.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic significance of clinicopathological and ultrasonographic features in anaplastic thyroid carcinoma beyond TERT promoter mutation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月5日

查看全文
  • Haejung Kim,
  • Goeun Park,
  • Myoung Kyoung Kim,
  • Young Lyun Oh,
  • Tae Hyuk Kim,
  • Jung Hee Shin,
  • Soo Yeon Hahn

摘要

TERT promoter mutation is associated with poor prognosis in differentiated thyroid carcinoma, with US features varying by mutation status. However, this correlation in anaplastic thyroid carcinoma (ATC) is understudied. We investigated the association between clinicopathological characteristics and US features of ATC with TERT mutation status and prognosis. From November 1994 to May 2022, 58 ATC nodules from 58 patients were analyzed. Two radiologists retrospectively reviewed US features based on the revised K-TIRADS and ACR-TIRADS. Of all 58 ATC nodules, 32 nodules were tested for TERT promoter mutation and detected in 11. TERT promoter-mutated ATC was larger than TERT wild-type ATC (p = 0.032); however, no other differences were observed. ATC with survival period of less than 12 months were more likely to have lymph node metastasis (p = 0.012) or distant metastasis at diagnosis (p < 0.001), larger size on US (p = 0.005), and suspicion for gross extrathyroidal extension on US (p = 0.04) compared to ATC with survival period of 12 months or more. Advanced disease at diagnosis was a critical factor associated with 1-year survival in patients with ATC, whereas the TERT promoter mutation status was not.